CBD Pioneer Launches New Digital Platform to Expand Into Non-Hemp Wellness Products
San Diego, Wednesday, 12 August 2026.
CV Sciences has launched PlusHLTH.com, expanding beyond its traditional CBD line to offer non-cannabinoid supplements, including plant-based protein with creatine, targeting general health and healthy aging markets.
Strategic Diversification Beyond Cannabinoids
CV Sciences, Inc. (OTCQB: CVSI) has officially expanded its digital footprint with the launch of PlusHLTH.com, a dedicated platform for non-cannabinoid wellness products [1]. Announced on August 11, 2026, this initiative marks a strategic pivot to diversify revenue streams beyond the company’s established hemp-derived CBD portfolio [1]. The platform utilizes a ‘Health Intelligence’ model designed to provide consumers with science-backed health solutions and personalized product recommendations [1]. This move addresses regulatory stagnation and shifting market demand by targeting the broader wellness and healthy aging sectors [1]. Joseph Dowling, Chief Executive Officer of CV Sciences, stated that the launch builds on the trust earned through the PlusCBD brand while supporting active lifestyles and everyday health [1].
Product Ecosystem and Health Intelligence
The new +PlusHLTH™ portfolio includes dietary supplements in capsule and gummy formats, alongside ‘Empowr,’ a plant-based protein formulation containing creatine [1]. The company intends to utilize the website as the primary hub for future innovation and consumer education as the brand grows [1]. CV Sciences operates with primary facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland, supporting its diverse product lines [2]. The +PlusCBD™ brand remains the top-selling hemp-extract brand in the natural products market per SPINS data and holds self-affirmed Generally Recognized as Safe (GRAS) status [2]. This foundational strength supports the expansion into non-cannabinoid nutritional solutions for health optimization [2].
Market Performance and Stock Data
As of the market close on August 11, 2026, CV Sciences stock was recorded at 0.0200 USD with a market capitalization of approximately 4.08 million USD [3]. The company engages in the development and sale of herbal supplements and plant-based food products under brand names including PlusCBD, PlusHLTH, and Cultured Foods [3]. Previous fiscal data indicates the company reported trailing twelve-month revenues of 13.38 million USD [3]. Investors and analysts monitor these metrics closely as the company executes its expansion strategy into general health and nutrition markets [3]. The stock has seen fluctuations within a 52-week range of 0.0196 USD to 0.1000 USD [3].
Upcoming Financial Disclosures and Industry Context
CV Sciences is scheduled to release financial results for the second quarter ended June 30, 2026, after market close on August 13, 2026 [2]. A conference call to discuss these results is planned for August 13, 2026, at 1:30 p.m. PT, accessible via webcast and telephone [5]. In the broader regulatory landscape, industry advocates such as the U.S. Hemp Roundtable have recently engaged with federal officials regarding hemp policy stability [4]. Senators and industry leaders continue to champion efforts to protect farmers and consumers of non-intoxicating hemp-derived products [4]. This regulatory environment remains a critical factor for companies diversifying within the botanical supplement space [4].